CA3103707C - Composition normalisee d'extrait d'alcaloide psychoactif - Google Patents

Composition normalisee d'extrait d'alcaloide psychoactif Download PDF

Info

Publication number
CA3103707C
CA3103707C CA3103707A CA3103707A CA3103707C CA 3103707 C CA3103707 C CA 3103707C CA 3103707 A CA3103707 A CA 3103707A CA 3103707 A CA3103707 A CA 3103707A CA 3103707 C CA3103707 C CA 3103707C
Authority
CA
Canada
Prior art keywords
composition
psychoactive
alkaloid
psychoactive alkaloid
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3103707A
Other languages
English (en)
Other versions
CA3103707A1 (fr
Inventor
Ryan Moss
Benjamin Lightburn
Lisa Ranken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psilo Scientific Ltd
Original Assignee
Psilo Scientific Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3103707A priority Critical patent/CA3103707C/fr
Application filed by Psilo Scientific Ltd filed Critical Psilo Scientific Ltd
Priority to BR112022025780A priority patent/BR112022025780A2/pt
Priority to IL299450A priority patent/IL299450A/en
Priority to CA3173030A priority patent/CA3173030C/fr
Priority to EP21825817.6A priority patent/EP4161546A4/fr
Priority to IL299449A priority patent/IL299449B2/en
Priority to IL305632A priority patent/IL305632B2/en
Priority to CA3169140A priority patent/CA3169140C/fr
Priority to IL297791A priority patent/IL297791B2/en
Priority to IL299448A priority patent/IL299448B2/en
Priority to PCT/CA2021/050813 priority patent/WO2021253116A1/fr
Priority to MX2022016533A priority patent/MX2022016533A/es
Priority to IL299451A priority patent/IL299451B2/en
Priority to IL299453A priority patent/IL299453B2/en
Priority to AU2021290454A priority patent/AU2021290454B2/en
Priority to IL298561A priority patent/IL298561B2/en
Priority to IL299452A priority patent/IL299452B2/en
Priority to US17/348,697 priority patent/US11331357B2/en
Priority to US17/351,149 priority patent/US11382942B2/en
Priority to US17/483,601 priority patent/US11298388B2/en
Priority to US17/587,731 priority patent/US11510952B2/en
Priority to US17/697,798 priority patent/US11571450B2/en
Priority to US17/702,701 priority patent/US11642385B2/en
Publication of CA3103707A1 publication Critical patent/CA3103707A1/fr
Priority to AU2022291414A priority patent/AU2022291414B2/en
Priority to AU2022291416A priority patent/AU2022291416B2/en
Priority to AU2022291411A priority patent/AU2022291411B2/en
Priority to AU2022291410A priority patent/AU2022291410B2/en
Priority to AU2022291413A priority patent/AU2022291413B2/en
Application granted granted Critical
Publication of CA3103707C publication Critical patent/CA3103707C/fr
Priority to AU2023285751A priority patent/AU2023285751B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/078—Psilocybe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une composition dalcaloïde psychoactif comprend, en pourcentage massique, de 0,1 % à 99,9 % dun extrait dalcaloïde psychoactif et de 0,1 % à 99,9 % dun excipient. Lextrait psychoactif peut comprendre une concentration dalcaloïde psychoactif de 0,1 % à 99,0 %, selon les étapes dépuration. Les excipients comprennent un support, un agent fluidifiant et/ou un préservatif. La composition est normalisée à une quantité précise souhaitée dun alcaloïde psychoactif, qui peut être précisément définie et répétée de lot en lot. La composition peut être en forme de poudre à écoulement libre et est donc facile à manipuler pendant le procédé demballage ou de tabulation. La composition peut aussi comprendre dautres excipients.
CA3103707A 2020-06-17 2020-12-18 Composition normalisee d'extrait d'alcaloide psychoactif Active CA3103707C (fr)

Priority Applications (29)

Application Number Priority Date Filing Date Title
CA3103707A CA3103707C (fr) 2020-12-18 2020-12-18 Composition normalisee d'extrait d'alcaloide psychoactif
IL299450A IL299450A (en) 2020-06-17 2021-06-14 Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
CA3173030A CA3173030C (fr) 2020-06-17 2021-06-14 Extraction d'alcaloide psychoactif principalement phosphoryle au moyen d'alcali
EP21825817.6A EP4161546A4 (fr) 2020-06-17 2021-06-14 Compositions comprenant des composés psychoactifs à partir d'organismes psychoactifs
IL299449A IL299449B2 (en) 2020-06-17 2021-06-14 Standardized psychoactive alkaloid extract composition
IL305632A IL305632B2 (en) 2020-06-17 2021-06-14 Extraction of Psychoactive compounds from Psychedelic Fungus
CA3169140A CA3169140C (fr) 2020-06-17 2021-06-14 Extraction d'alcaloides psychoactifs capables de phosphorylation a dephosphorylation controlee
IL297791A IL297791B2 (en) 2020-06-17 2021-06-14 Extraction of psychoactive compounds from psychedelic mushrooms
IL299448A IL299448B2 (en) 2020-06-17 2021-06-14 Process for obtaining a purified psychoactive alkaloid solution
PCT/CA2021/050813 WO2021253116A1 (fr) 2020-06-17 2021-06-14 Compositions comprenant des composés psychoactifs à partir d'organismes psychoactifs
MX2022016533A MX2022016533A (es) 2020-06-17 2021-06-14 Composiciones que comprenden compuestos psicoactivos de organismos psicoactivos.
IL299451A IL299451B2 (en) 2020-06-17 2021-06-14 Predominantly phosphorylated psychoactive alkaloid extraction using alkali
IL299453A IL299453B2 (en) 2020-06-17 2021-06-14 Psychoactive alkaloid extraction and composition with inhibited dephosphorylation
AU2021290454A AU2021290454B2 (en) 2020-06-17 2021-06-14 Process for Obtaining a Purified Psychoactive Alkaloid Solution
BR112022025780A BR112022025780A2 (pt) 2020-06-17 2021-06-14 Método para gerar um extrato de alcaloide psicoativo, método para gerar um extrato de alcaloide psicoativo fosforilado e método para gerar um extrato de alcaloide psicoativo desfosforilado
IL299452A IL299452B2 (en) 2020-06-17 2021-06-14 Extraction and synthesis of psychoactive alkaloids with controlled dephosphorylation
IL298561A IL298561B2 (en) 2020-06-17 2021-06-14 Methanol-based extraction of psychoactive compounds from mushrooms
US17/348,697 US11331357B2 (en) 2020-06-17 2021-06-15 Methods and compositions comprising psychoactive compounds from psychoactive organisms
US17/351,149 US11382942B2 (en) 2020-06-17 2021-06-17 Extraction of psychoactive compounds from psilocybin fungus
US17/483,601 US11298388B2 (en) 2020-06-17 2021-09-23 Psychoactive alkaloid extraction and composition with controlled dephosphorylation
US17/587,731 US11510952B2 (en) 2020-06-17 2022-01-28 Ethanol extraction of psychoactive compounds from psilocybin fungus
US17/697,798 US11571450B2 (en) 2020-06-17 2022-03-17 Aqueous extraction of psychoactive compounds from psilocybin fungus
US17/702,701 US11642385B2 (en) 2020-06-17 2022-03-23 Basic extraction of psychoactive compounds from psychoactive organisms
AU2022291414A AU2022291414B2 (en) 2020-06-17 2022-12-19 Psychoactive alkaloid extraction and composition with controlled dephosphorylation
AU2022291416A AU2022291416B2 (en) 2020-06-17 2022-12-19 Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
AU2022291411A AU2022291411B2 (en) 2020-06-17 2022-12-19 Psychoactive alkaloid extraction and composition with inhibited dephosphorylation
AU2022291410A AU2022291410B2 (en) 2020-06-17 2022-12-19 Standardized psychoactive alkaloid extract composition
AU2022291413A AU2022291413B2 (en) 2020-06-17 2022-12-19 Predominantly phosphorylated psychoactive alkaloid extraction using alkali
AU2023285751A AU2023285751B2 (en) 2020-06-17 2023-12-19 Powdered Composition Containing a Mushroom Extract Comprising a Psychoactive Alkaloid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3103707A CA3103707C (fr) 2020-12-18 2020-12-18 Composition normalisee d'extrait d'alcaloide psychoactif

Publications (2)

Publication Number Publication Date
CA3103707A1 CA3103707A1 (fr) 2022-06-18
CA3103707C true CA3103707C (fr) 2023-09-26

Family

ID=82016145

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3103707A Active CA3103707C (fr) 2020-06-17 2020-12-18 Composition normalisee d'extrait d'alcaloide psychoactif

Country Status (1)

Country Link
CA (1) CA3103707C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12642787B2 (en) 2020-05-08 2026-06-02 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2023053090A1 (fr) * 2021-10-01 2023-04-06 Optimi Health Corp. Technique d'extraction
US12551519B2 (en) 2022-04-25 2026-02-17 VCENNA Technology & Labs Inc. Extraction system and method for organic metabolites
WO2025153822A1 (fr) * 2024-01-18 2025-07-24 Beckley Psytech Limited Formulations de poudre de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12642787B2 (en) 2020-05-08 2026-06-02 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions
US12685722B2 (en) 2020-05-08 2026-07-21 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions
US12691098B2 (en) 2020-05-08 2026-07-28 Atai Therapeutics, Inc. Compositions of matter and pharmaceutical compositions

Also Published As

Publication number Publication date
CA3103707A1 (fr) 2022-06-18

Similar Documents

Publication Publication Date Title
US11510952B2 (en) Ethanol extraction of psychoactive compounds from psilocybin fungus
CA3169140C (fr) Extraction d'alcaloides psychoactifs capables de phosphorylation a dephosphorylation controlee
CA3103707A1 (fr) Composition normalisee d'extrait d'alcaloide psychoactif
US11382942B2 (en) Extraction of psychoactive compounds from psilocybin fungus
CA3097246C (fr) Processus d`obtention d`une solution alcaloide psychoactive purifiee
EP4161549A1 (fr) Procédé d'obtention d'une solution purifiée d'alcaloïde psychoactif
CA3137016C (fr) Extraction d'alcaloide psychoactif et composition avec dephosphorylationattenuees
CN101133827B (zh) 菠萝蜜提取物在解酒方面的应用

Legal Events

Date Code Title Description
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241127

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241127

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121